A bitter battle is brewing between two renowned cancer care institutions, with a messy breakup leading to a complex web of employment issues. The story begins with a corporate divorce, as Mass General Brigham (MGB) parted ways with Dana-Farber, its long-time partner. But here's where it gets controversial: MGB, in a swift move, plans to cut ties with Dana-Farber's physician assistants, leaving their future uncertain.
According to an internal email, MGB intends to phase out these assistants, starting in April, with the goal of having them all replaced by the end of the year. The email, sent by Dana-Farber's chief medical officer, Dr. Craig Bunnell, reveals an attempt at a 'mutually agreed upon transition plan', but it seems this plan fell through.
"This is not the transition we envisioned," Bunnell stated, emphasizing the point.
And this is the part most people miss: MGB, in a surprising twist, offered these assistants a way out of their employment limbo - a job at MGB itself.
"We want you on our team," MGB executives wrote, extending an olive branch.
The tensions between these organizations have been simmering for years, with Dana-Farber pushing for its own hospital and vision, while MGB integrated its flagship hospitals. But the fight over these physician assistants showcases a heightened competition between the institutions.
Gary J. Young, a professor at Northeastern University, puts it bluntly: "This is a medical arms race. Each institution is vying to be the leading cancer center, and that requires significant investment."
This situation could lead to increased healthcare spending in the short term, as both institutions invest in technology and recruit top talent. In the long run, the consolidation of cancer care in Boston might impact community hospitals, potentially raising overall healthcare costs.
There are already signs of this, with MGB offering extra pay to its physician assistants to work at a new cancer unit.
Publicly, both hospitals emphasize patient care, declining to comment on the specifics of their negotiations.
The separation of these closely intertwined organizations is particularly challenging, especially considering their long history of collaboration. For decades, Dana-Farber patients received outpatient care at Dana-Farber, while inpatient care was provided at Brigham and Women's. This seamless transition is now at risk.
As of now, the two sides haven't signed an agreement on transition services, leaving many details up in the air.
Dana-Farber and MGB had been working towards an agreement to minimize disruption, but MGB's recent move "represents a departure from those expectations," according to Bunnell's email.
MGB justifies its actions by citing the need for a staffed, trained, and stable team to support inpatient oncology patients by 2028. However, the uncertainty surrounding Dana-Farber's timeline for moving patients and staff elsewhere adds to the complexity.
It's unclear how many physician assistants will be affected, and whether Dana-Farber is providing job security for those who choose to stay.
Even if MGB manages to entice more clinicians to its in-house cancer initiative, the program itself is in a state of flux, with most advanced practice providers recently unionizing.
As the organizations navigate this complex separation, they are also acutely aware of the financial implications. The stakes are high, with MGB stating that 40% of all Brigham surgeries are cancer-related. Brigham aims to maintain its position in cancer treatment, while for Dana-Farber, cancer care is their entire business.
This provider dispute is just the latest chapter in a series of tete-a-tetes between the two institutions. As Dana-Farber sought to build its new cancer hospital, MGB raised objections. In response, MGB announced a $400 million cancer initiative between its flagship hospitals.
While many regulatory and other approvals are in place for Dana-Farber and BI, the realization of these new visions is far from certain.
The question remains: will patients notice these tensions, and how will health insurers dictate access to these facilities?
"They want patients to experience seamless care," Young said. "But pulling that off will be tricky, as there are substantial challenges behind the scenes."
The story continues to unfold, leaving us with a thought-provoking question: In this battle for cancer care supremacy, who will ultimately win, and at what cost?
